On Feb. 17, 2021, Altimmune announced that the FDA had cleared the Companyﾒs Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID, a novel, single-dose, intranasal COVID-19 vaccine candidate. Altimmune expected to commence patient enrollment in the Phase 1 clinical trial in the following week.